Kinathera Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Liquidation

Kinathera General Information

Description

Operator of a pharmaceutical company intended to bring a pharmacological therapeutic approach for the treatment of immunofibrotic autoimmune diseases. The company develops oral chemical entities specific for the inhibition of TBK1/IKKe in rare immuno-fibrotic diseases such as scleroderma or lupus nephritis, with animal proof of concept in therapeutic mode on pulmonary fibrosis and modulation of Type I interferon and autoantibodies, enabling physicians to improve human quality of life.

Contact Information

Formerly Known As
Balmes Transplantation
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 163 avenue de Luminy, Luminy Biotech Entreprises
  • Bâtiment Béret-Delaage, Case 922
  • 13288 Marseille
  • France
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 163 avenue de Luminy, Luminy Biotech Entreprises
  • Bâtiment Béret-Delaage, Case 922
  • 13288 Marseille
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kinathera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 03-Apr-2024 Completed Bankruptcy: Liquidation
9. Seed Round 09-Aug-2023 Completed Pre-Clinical Trials
8. Accelerator/Incubator 01-Aug-2022 Completed Pre-Clinical Trials
7. Secondary Transaction - Private Completed Pre-Clinical Trials
6. Seed Round 13-Jun-2022 Completed Pre-Clinical Trials
5. Seed Round 22-Dec-2017 Completed Pre-Clinical Trials
4. Angel (individual) Completed Startup
3. Grant Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Kinathera’s complete valuation and funding history, request access »

Kinathera Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
To view Kinathera’s complete cap table history, request access »

Kinathera Patents

Kinathera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3095755-A1 New cytoprotective drugs Inactive 10-May-2019
WO-2020229761-A1 Novel cytoprotective medicaments Inactive 10-May-2019
US-11458189-B2 Cytoprotective drugs Inactive 17-Nov-2017
FR-3073738-A1 New cytoprotective medicines Inactive 17-Nov-2017
AU-2018366352-A1 Novel cytoprotective drugs Inactive 17-Nov-2017 A61K38/12
To view Kinathera’s complete patent history, request access »

Kinathera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kinathera FAQs

  • When was Kinathera founded?

    Kinathera was founded in 2015.

  • Where is Kinathera headquartered?

    Kinathera is headquartered in Marseille, France.

  • What is the size of Kinathera?

    Kinathera has 5 total employees.

  • What industry is Kinathera in?

    Kinathera’s primary industry is Biotechnology.

  • Is Kinathera a private or public company?

    Kinathera is a Private company.

  • What is Kinathera’s current revenue?

    The current revenue for Kinathera is .

  • How much funding has Kinathera raised over time?

    Kinathera has raised $29.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process